Moderna, COVID-19
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in the fall of 2024." The organization recommends a six-month interval between COVID vaccines, "with a minimum of three months from the last dose."
Why Australia could miss out on Moderna's new COVID-19 vaccine
While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the government seemingly only intends to make one available to the public.
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine.Moderna's Spikevax KP.2 targets the KP.2 variant of the virus.The U.S. Food and Drug Administration has also approved the shot,
FDA OKs third dose for Pfizer and Moderna Covid-19 vaccines
These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing organisations (CMOs) (see BIO 2021: mRNA Vaccine Booster Shots for Covid-19 and Increasing Uptake Will Offer CMOs Lucrative Opportunities,
New COVID-19 vaccine by Moderna approved by Health Canada
The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve
Moderna Shares Rise on Canada Government Approval of Updated Covid-19 Vaccine
The biotechnology company on Tuesday said that Health Canada authorized the vaccine targeting the KP.2 Covid-19 variant of Sars-Cov-2 and will begin delivery of updated doses to the Public Health Agency of Canada.
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity ...
Pfizer Advances On Its Cancer Journey
Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
Investor's Business Daily on MSN5d
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.
AOL9d
Moderna expects up to $3.5 billion in 2025 sales
The FDA approved Moderna's mRESVIA shot for RSV-associated lower respiratory tract disease in adults aged 60 or older last ...
Moderna forecasts lower sales next year, shares near four-year low
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
Moderna, Eli Lilly, and other drug firms in Greater Boston have become galleries for disadvantaged artists
Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...
Lightning Round: Buy more Pfizer, says Jim Cramer
Pfizer, First Solar, Six Flags, Equity Residential, Vertiv, Moderna, and Powell Industries. Donald Trump Suffers Major Blow ...